Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus

Neurology

Volumn 81, Issue 22, 2013, Pages 1891-1899

  Ottoboni, Linda ^a,d   Frohlich, Irene Y ^a,d   Lee, Michelle ^a,d   Healy, Brian C ^b   Keenan, Brendan T ^a,d   Xia, Zongqi ^a,d   Chitnis, Tanuja ^b   Guttmann, Charles R ^c   Khoury, Samia J ^b   Weiner, Howard L ^b   Hafler, David A ^b,e   Jager, Philip L De ^a,d  

^a Program in Translational NeuroPsychiatric Genomics   (United States)

^b Department of Neurology   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AA 5 Amino Acids; BWH 5 Brigham and Women's Hospital; CI 5 Confidence Interval; GA 5 Glatiramer Acetate; IFN b 5 Interferon B; MAPK 5 Mitogen Activated Protein Kinase; MS 5 Multiple Sclerosis; MSSS 5 Multiple Sclerosis Severity Scale; NF 5 Nuclear Factor; PBMC 5 Peripheral Blood Mononuclear Cell; STNFRSF1A 5 soluble TNFRSF1A; TNF 5 tumor necrosis factor; TRAPS 5 TNF receptor associated periodic syndrome.

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RNA ISOFORM; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; CYTOPLASM; DISEASE COURSE; FEMALE; GENE LOCUS; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RADIOGRAPHY; SERUM; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE;

ANIMALS; ARGININE; CHEMOKINE CXCL10; FEMALE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTAMINE; HEK293 CELLS; HUMANS; IMMUNOLOGIC FACTORS; LONGITUDINAL STUDIES; MALE; MONOCYTES; MULTIPLE SCLEROSIS; MUTATION; PHORBOL ESTERS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RNA ISOFORMS; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84891944587     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000436612.66328.8a     Document Type: Article

References (36)

1. Prajapati R, Plant D, Barton A. Genetic and genomic predictors of anti-TNF response. Pharmacogenomics 2011;12:1571-1585.
2. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization inMS: results of a randomized, placebocontrolled multicenter study. Neurology 1999;53:457-465.
3. Minden K, Aganna E, McDermott MF, Zink A. Tumour necrosis factor receptor associated periodic syndrome (TRAPS) with central nervous system involvement. Ann Rheum Dis 2004;63:1356-1357.
4. Hoffmann LA, Lohse P, Konig FB, Feneberg W, Hohlfeld R, Kumpfel T. TNFRSF1A R92Q mutation in association with a multiple sclerosis-like demyelinating syndrome. Neurology 2008;70:1155-1156.
5. De Jager PL, Jia X, Wang J, et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 2009;41:776-782.
6. International Multiple Sclerosis Genetic Consortium. The genetic association of variants in CD6, TNFRSF1A and IRF8 to multiple sclerosis: a multicenter case-control study. PLoS One 2011;6:e18813.
7. Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011;476:214-219.
8. Patsopoulos NA, de Bakker PI. Genome-wide metaanalysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol 2011;70:897-912.
9. Gregory AP, Dendrou CA, Attfield KE, et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 2012;488:508-511.
10. Comabella M, Caminero AB, Malhotra S, et al. TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosis. Neurology 2013;80:2010-2016.
11. Yarilina A, Park-Min KH, Antoniv T, Hu X, Ivashkiv LB. TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon-response genes. Nat Immunol 2008;9: 378-387.
12. Yarilina A, Ivashkiv LB. Type I interferon: a new player in TNF signaling. Curr Dir Autoimmun 2010;11:94-104.
13. Gross R, Healy BC, Cepok S, et al. Population structure and HLA DRB1 1501 in the response of subjects with multiple sclerosis to first-line treatments. J Neuroimmunol 2011;233:168-174.
14. Xia Z, Liu Q, Berger CT, et al. A 17q12 allele is associated with altered NK cell subsets and function. J Immunol 2012;188:3315-3322.
15. Baranzini SE, Wang J, Gibson RA, et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet 2009;18:767-778.
16. International Multiple Sclerosis Genetics Consortium. Genome-wide association study of severity in multiple sclerosis. Genes Immun 2011;12:615-625.
17. Todd I, Radford PM, Draper-Morgan KA, et al. Mutant forms of tumour necrosis factor receptor I that occur in TNF-receptor-associated periodic syndrome retain signalling functions but show abnormal behaviour. Immunology 2004;113:65-79.
18. Lobito AA, Kimberley FC, Muppidi JR, et al. Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood 2006; 108:1320-1327.
19. Simon A, Park H, Maddipati R, et al. Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome. Proc Natl Acad Sci USA 2010;107:9801-9806.
20. Goris A, Fockaert N, Cosemans L, et al. TNFRSF1A coding variants in multiple sclerosis. J Neuroimmunol 2011; 235:110-112.
21. Kauffman MA, Gonzalez-Moron D, Garcea O, Villa AM. TNFSFR1A R92Q mutation, autoinflammatory symptoms and multiple sclerosis in a cohort from Argentina. Mol Biol Rep 2012;39:117-121.
22. McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999;97:133-144.
23. Stojanov S, Dejaco C, Lohse P, et al. Clinical and functional characterisation of a novel TNFRSF1A c.605T.A/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment. Ann Rheum Dis 2008;67:1292-1298.
24. Zhang Z, Oliver P, Lancaster JR Jr, et al. Reactive oxygen species mediate tumor necrosis factor alpha-converting, enzyme-dependent ectodomain shedding induced by phorbol myristate acetate. FASEB J 2001;15:303-305.
25. Scott AJ, O'Dea KP, O'Callaghan D, et al. Reactive oxygen species and p38 mitogen-activated protein kinase mediate tumor necrosis factor alpha-converting enzyme (TACE/ADAM-17) activation in primary human monocytes. J Biol Chem 2011;286:35466-35476.
26. Ebert EC, Panja A, Praveen R. Human intestinal intraepithelial lymphocytes and epithelial cells coinduce interleukin-8 production through the CD2-CD58 interaction. Am J Physiol Gastrointest Liver Physiol 2009; 296:G671-G677.
27. Smolders J, Schuurman KG, van Strien ME, et al. Expression of vitamin D receptor and metabolizing enzymes in multiple sclerosis-affected brain tissue. J Neuropathol Exp Neurol 2013;72:91-105.
28. Park JH, Yu Q, Erman B, et al. Suppression of IL7Ralpha transcription by IL-7 and other prosurvival cytokines: a novel mechanism for maximizing IL-7-dependent T cell survival. Immunity 2004;21:289-302.
29. Zhao B, Grimes SN, Li S, Hu X, Ivashkiv LB. TNFinduced osteoclastogenesis and inflammatory bone resorption are inhibited by transcription factor RBP-J. J Exp Med 2012;209:319-334.
30. Simpson JE, Newcombe J, Cuzner ML, Woodroofe MN. Expression of the interferon-gamma-inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions. Neuropathol Appl Neurobiol 2000;26: 133-142.
31. Ifergan I, Wosik K, Cayrol R, et al. Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Ann Neurol 2006;60:45-55.
32. Gregory SG, Schmidt S, Seth P, et al. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 2007;39: 1083-1091.
33. Maier LM, Anderson DE, Severson CA, et al. Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J Immunol 2009; 182:1541-1547.
34. De Jager PL, Baecher-Allan C, Maier LM, et al. The role of the CD58 locus in multiple sclerosis. Proc Natl Acad Sci USA 2009;106:5264-5269.
35. Kofler DM, Severson CA, Mousissian N, De Jager PL, Hafler DA. The CD6 multiple sclerosis susceptibility allele is associated with alterations in CD41 T cell proliferation. J Immunol 2011;187:3286-3291.
36. Ramagopalan SV, Dyment DA, Cader MZ, et al. Rare variants in the CYP27B1 gene are associated with multiple sclerosis. Ann Neurol 2011;70:881-886.